Adaptimmune Therapeutics plc [ADAP] shares are up more than 688.68% this year and recently increased 0.08% or $0.71 to settle at $9.07. Analysts expect ADAP to grow earnings at a 1.00% annual rate over the next 5 years. ADAP has a short ratio of 7.00. This implies that the market is currently less bullish on the outlook for ADAP.

On 28, August 2020, Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients. According to news published on Yahoo Finance, Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from its Phase 1 trial with SPEAR T-cells targeting AFP at the virtual International Liver Congress (ILC). One patient out of four dosed with 5 billion or more cells had a complete response, which was reported previously. The data also demonstrate an acceptable safety profile in patients with hepatocellular carcinoma (HCC).

Analyst Birdseye View:

The most recent analyst activity for Adaptimmune Therapeutics plc [NASDAQ:ADAP] stock was on August 02, 2019, when it was Downgrade with a Neutral rating from Guggenheim. Before that, on April 22, 2020, Mizuho Recapitulated a Neutral rating and elevated its amount target to $3. On May 31, 2019, ROTH Capital Initiated a Buy rating. On May 30, 2019, Citigroup Resumed a Buy rating. On May 07, 2019, SVB Leerink Downgrade a Mkt perform rating and decreased its price target to $5. On March 17, 2017, Wells Fargo Initiated a Market perform rating. On October 24, 2016, BofA/Merrill Downgrade an Underperform rating. On September 30, 2016 Raymond James Initiated an Outperform rating and elevated its amount target to $16.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.71 and a peak of $13.40. Right now, the middling Wall Street analyst 12-month amount mark is $12.50. At the most recent market close, shares of Adaptimmune Therapeutics plc [NASDAQ:ADAP] were valued at $9.07. According to the average price forecast, investors can expect a potential return of -1.36%.


Adaptimmune Therapeutics plc [NASDAQ:ADAP] most recently reported quarterly sales of 503.2 million, which represented growth of 150.00%. This publicly-traded organization’s revenue is $2,817 per employee, while its income is -$344,332 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -60.11, -74.35, -78.03 and -70.01 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 17.08 and the whole liability to whole assets at 14.02. It shows enduring liability to the whole principal at 15.40 and enduring liability to assets at 0.13 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 8.14 points at 1st support level, the second support level is making up to 7.91. But as of 1st resistance point, this stock is sitting at 8.61 and at 8.86 for 2nd resistance point.

Adaptimmune Therapeutics plc [ADAP] reported its earnings at -$0.24 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.23/share signifying the difference of -0.01 and -4.30% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.24 calling estimates for -$0.25/share with the difference of 0.01 depicting the surprise of 4.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Adaptimmune Therapeutics plc [NASDAQ:ADAP] is 11.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.61. Now if looking for a valuation of this stock’s amount to sales ratio it’s 111.80 and it’s amount to book ratio is 1.02.

Insider Stories

The most recent insider trade was by Rawcliffe Adrian, Chief Executive Officer, and it was the sale of 2776.0 shares on Sep 01. TAYTON-MARTIN HELEN KATRINA, the Chief Business Officer, completed a sale of 0.2 million shares on Aug 03. On Aug 03, Lunger John, Chief Patient Supply Officer, completed a sale of 4823.0 shares.